Literature DB >> 28127179

Molecular and Functional Diagnostic Tools in Precision Oncology for Urological Malignancies.

Vasanthakumar Sekar1, Debapriya Ghosh Mehrotra2, Biswanath Majumder2.   

Abstract

Urological malignancies, represented mainly by prostate, bladder, and renal cancers, are some of the leading causes of cancer-related mortalities worldwide. Despite various efforts over decades to develop early detection tests and effective therapeutic paradigms, the response rate to the existing treatments remains low for both primary and late stage/recurrent phases of these cancers. The evolving landscape of molecular diagnostics, aiming to make the diagnosis and treatment more patient-driven, underpins precision oncology and particularly intends to rationally profile individual tumors and highlight the mechanistic insight and complexity of tumor microenvironment in order to develop biomarkers of toxicity risks and response prediction in a clinically oriented dynamical setting. The present review is an effort to capture some of the recent developments in the area of molecular diagnostics and functional testing platforms and their potential application in clinical decision making in the premises of precision oncology of urological malignancies.

Entities:  

Keywords:  Ex vivo models; Precision therapy; Prediction biomarkers; Urological cancer

Year:  2016        PMID: 28127179      PMCID: PMC5236026          DOI: 10.1007/s13193-016-0591-4

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  81 in total

1.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Authors:  Yung-Jue Bang; Eric Van Cutsem; Andrea Feyereislova; Hyun C Chung; Lin Shen; Akira Sawaki; Florian Lordick; Atsushi Ohtsu; Yasushi Omuro; Taroh Satoh; Giuseppe Aprile; Evgeny Kulikov; Julie Hill; Michaela Lehle; Josef Rüschoff; Yoon-Koo Kang
Journal:  Lancet       Date:  2010-08-19       Impact factor: 79.321

2.  Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy.

Authors:  Joan Montero; Kristopher A Sarosiek; Joseph D DeAngelo; Ophélia Maertens; Jeremy Ryan; Dalia Ercan; Huiying Piao; Neil S Horowitz; Ross S Berkowitz; Ursula Matulonis; Pasi A Jänne; Philip C Amrein; Karen Cichowski; Ronny Drapkin; Anthony Letai
Journal:  Cell       Date:  2015-02-26       Impact factor: 41.582

3.  A molecular signature predictive of indolent prostate cancer.

Authors:  Shazia Irshad; Mukesh Bansal; Mireia Castillo-Martin; Tian Zheng; Alvaro Aytes; Sven Wenske; Clémentine Le Magnen; Paolo Guarnieri; Pavel Sumazin; Mitchell C Benson; Michael M Shen; Andrea Califano; Cory Abate-Shen
Journal:  Sci Transl Med       Date:  2013-09-11       Impact factor: 17.956

4.  An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors.

Authors:  Oliver Jonas; Heather M Landry; Jason E Fuller; John T Santini; Jose Baselga; Robert I Tepper; Michael J Cima; Robert Langer
Journal:  Sci Transl Med       Date:  2015-04-22       Impact factor: 17.956

5.  Diagnostic Utility of the ImmunoCyt/uCyt+ Test in Bladder Cancer.

Authors:  Kirsten L Greene; Anna Berry; Badrinath R Konety
Journal:  Rev Urol       Date:  2006

6.  Structural basis for antagonism and resistance of bicalutamide in prostate cancer.

Authors:  Casey E Bohl; Wenqing Gao; Duane D Miller; Charles E Bell; James T Dalton
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-15       Impact factor: 11.205

7.  Constitutive mRNA expression of DNA repair-related genes as a biomarker for clinical radio-resistance: A pilot study in prostate cancer patients receiving radiotherapy.

Authors:  Jörg Hümmerich; Gisela Werle-Schneider; Odilia Popanda; Oktay Celebi; Jenny Chang-Claude; Silke Kropp; Claudia Mayer; Jürgen Debus; Helmut Bartsch; Peter Schmezer
Journal:  Int J Radiat Biol       Date:  2006-08       Impact factor: 2.694

Review 8.  Biomarkers in prostate cancer surveillance and screening: past, present, and future.

Authors:  K Clint Cary; Mathew R Cooperberg
Journal:  Ther Adv Urol       Date:  2013-12

9.  Newly characterised ex vivo colospheres as a three-dimensional colon cancer cell model of tumour aggressiveness.

Authors:  L-B Weiswald; S Richon; P Validire; M Briffod; R Lai-Kuen; F P Cordelières; F Bertrand; D Dargere; G Massonnet; E Marangoni; B Gayet; M Pocard; I Bieche; M-F Poupon; D Bellet; V Dangles-Marie
Journal:  Br J Cancer       Date:  2009-07-14       Impact factor: 7.640

10.  Analysis of gene expression using gene sets discriminates cancer patients with and without late radiation toxicity.

Authors:  J Peter Svensson; Lukas J A Stalpers; Rebecca E E Esveldt-van Lange; Nicolaas A P Franken; Jaap Haveman; Binie Klein; Ingela Turesson; Harry Vrieling; Micheline Giphart-Gassler
Journal:  PLoS Med       Date:  2006-10       Impact factor: 11.069

View more
  1 in total

1.  Accuracy of the urine UCA1 for diagnosis of bladder cancer: a meta-analysis.

Authors:  Xiangrong Cui; Xuan Jing; Chunlan Long; Qin Yi; Jie Tian; Jing Zhu
Journal:  Oncotarget       Date:  2017-05-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.